• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Efficacy.pdf
    Size:
    149.2Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Krebs, Matthew G
    De Braud, F.
    Siena, S.
    Drilon, A.
    Doebele, R. C.
    Patel, M. R.
    Cho, B. C.
    Liu, S. V.
    Ahn, M. J.
    Chiu, C. H.
    Farago, A. F.
    Lin, C. C.
    Karapetis, C. S.
    Li, Y. C.
    Barlesi, F.
    Simmons, B.
    Pitcher, B.
    Dziadziuszko, R.
    Show allShow less
    Affiliation
    Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester,
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background: Entrectinib is a potent, selective, CNS active, ROS1 tyrosine kinase inhibitor (TKI). In a preliminary analysis (data cut-off: 31 May 2018) of pts with ROS1 fusion-positive (ROS1-fp) NSCLC enrolled in phase 1/2 studies (ALKA-372-001, STARTRK-1, STARTRK-2; EudraCT 2012-000148-88, NCT02097810, NCT02568267), treatment with entrectinib produced clinically meaningful and durable systemic responses with a manageable safety profile. We report on an updated integrated analysis in a larger patient population with longer follow-up (data cut-off: 1 May 2019). Methods: Enrolled pts were ROS1 TKI naïve with measurable disease; most received entrectinib 600mg once daily. Tumours were assessed by blinded independent central review using RECIST v1.1, after 4 wks and every 8 wks thereafter. Primary endpoints were objective response rate (ORR) and duration of response (DoR). Progression-free survival (PFS), overall survival (OS), efficacy in pts with/without baseline CNS metastases, and safety were also assessed. Results: The efficacy-evaluable population comprised 161 pts with ROS1-fp NSCLC; baseline characteristics are shown (Table). Median follow-up: 15.8 months (range 0.1e43.2). ORR, 67.1% (95% CI 59.3e74.3); 14 pts (8.7%) achieved complete response, 94 (58.4%) partial response, 14 (8.7%) stable disease, 15 (9.3%) disease progression. Median DoR, 15.7 months (95% CI 13.9e28.6); median PFS, 15.7 months (95% CI 11.0e21.1); median OS, not estimable (NE) (95% CI 28.3eNE). In the subgroup with prior immunotherapy (n¼24), ORR, 70.8% (95% CI 48.9e87.4). In pts with investigator-assessed CNS metastases at baseline, ORR, 62.5% (95% CI 48.6e75.1). The safety profile was similar to that previously reported. Conclusions: This updated analysis, using a larger dataset with longer follow-up, shows that entrectinib induces clinically meaningful responses in pts with ROS1-fp NSCLC, including pts with CNS metastases at baseline.
    Citation
    Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, et al. 1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis. Annals of Oncology. 2020;31:S831-S3.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/623474
    DOI
    10.1016/j.annonc.2020.08.1601
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2020.08.1601
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2020.08.1601
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.